EGFR and ovarian carcinoma: We further examined the EGFR expression status in the retrieved tumor samples and found that monensin treatment groups exhibited drastically diminished EGFR expression relative to the control group (Fig. 7Cpanelsg vs. h,i), consistent with earlier findings (Fig. 4B,C) and strengthening the proposition that EGFR may serve as a key cellular target explaining anti-proliferative effects of monensin in human ovarian cancer cells.